1. Home
  2. LIXT vs NWGL Comparison

LIXT vs NWGL Comparison

Compare LIXT & NWGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LIXT
  • NWGL
  • Stock Information
  • Founded
  • LIXT 2005
  • NWGL 2008
  • Country
  • LIXT United States
  • NWGL Macau
  • Employees
  • LIXT N/A
  • NWGL N/A
  • Industry
  • LIXT Biotechnology: Pharmaceutical Preparations
  • NWGL
  • Sector
  • LIXT Health Care
  • NWGL
  • Exchange
  • LIXT Nasdaq
  • NWGL Nasdaq
  • Market Cap
  • LIXT 20.5M
  • NWGL 22.8M
  • IPO Year
  • LIXT N/A
  • NWGL 2023
  • Fundamental
  • Price
  • LIXT $4.00
  • NWGL $1.22
  • Analyst Decision
  • LIXT
  • NWGL
  • Analyst Count
  • LIXT 0
  • NWGL 0
  • Target Price
  • LIXT N/A
  • NWGL N/A
  • AVG Volume (30 Days)
  • LIXT 86.0K
  • NWGL 15.5K
  • Earning Date
  • LIXT 11-12-2025
  • NWGL 04-24-2026
  • Dividend Yield
  • LIXT N/A
  • NWGL N/A
  • EPS Growth
  • LIXT N/A
  • NWGL N/A
  • EPS
  • LIXT N/A
  • NWGL N/A
  • Revenue
  • LIXT N/A
  • NWGL $21,539,347.00
  • Revenue This Year
  • LIXT N/A
  • NWGL N/A
  • Revenue Next Year
  • LIXT N/A
  • NWGL N/A
  • P/E Ratio
  • LIXT N/A
  • NWGL N/A
  • Revenue Growth
  • LIXT N/A
  • NWGL N/A
  • 52 Week Low
  • LIXT $0.64
  • NWGL $0.91
  • 52 Week High
  • LIXT $6.26
  • NWGL $6.61
  • Technical
  • Relative Strength Index (RSI)
  • LIXT 41.53
  • NWGL 35.20
  • Support Level
  • LIXT $4.14
  • NWGL $0.99
  • Resistance Level
  • LIXT $4.49
  • NWGL $1.23
  • Average True Range (ATR)
  • LIXT 0.42
  • NWGL 0.09
  • MACD
  • LIXT 0.00
  • NWGL -0.02
  • Stochastic Oscillator
  • LIXT 34.03
  • NWGL 22.37

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

About NWGL Nature Wood Group Limited

Nature Wood Group Ltd is a vertically-integrated forestry company that focuses on FSC business operations. It produces various products, including logs, decking, flooring, sawn timber, recycled charcoal, synthesized charcoal, machine-made charcoal, and essential oils. The Group owns natural forest concessions and cutting rights for exploiting timbers on parcels of land in Peru. The Group is organized into two operating divisions; Direct Purchase and Original Design Manufacturer (ODM) Services, and Manufacturing segments. The Direct Purchase and ODM Segment that derives the majority of revenue engages in the business of sourcing live wood and owning designed designs on wood products for sales to end customers. Geographically, the company generates a majority of its revenue from China.

Share on Social Networks: